🧬 AMX0035 Shows Sustained Benefit in Wolfram Syndrome at 48 Weeks

Amylyx Pharmaceuticals has reported positive long-term results from its Phase 2 HELIOS trial evaluating AMX0035 in individuals with Wolfram syndrome, a rare, progressive neurodegenerative disease. At 48 weeks, the treatment continued to demonstrate improvements or stabilization across multiple disease domains, suggesting durable therapeutic benefit.

​

🔍 Key Highlights

Pancreatic Function: C-peptide response—a marker of residual beta-cell activity—showed further improvement at 48 weeks, indicating sustained pancreatic function.

Glycemic Control: Participants experienced improved blood sugar regulation, with a modest reduction in HbA1c and increased time in the target glucose range.

Visual Acuity: Average visual function stabilized or improved slightly, as measured by changes in LogMAR scores.

Clinician and Patient Impression: All participants met responder criteria on both clinician- and self-rated global impression scales, indicating either stability or perceived improvement in overall health.

Safety: AMX0035 remained well-tolerated with no serious adverse events related to treatment reported over the study duration.

1. 🧠 Wolfram Syndrome: Clinical Spectrum and Neurological Features

Wolfram syndrome (DIDMOAD) is characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, often progressing to neurodegeneration, ataxia, and brainstem dysfunction. Neurologists play a key role in early recognition, especially when visual or sensory symptoms precede metabolic signs.

2. 🧬 Molecular Pathophysiology: ER Stress and Mitochondrial Dysfunction

Mutations in the WFS1 gene lead to chronic endoplasmic reticulum (ER) stress, impaired calcium homeostasis, and mitochondrial dysfunction. These mechanisms contribute to progressive neuronal and β-cell loss — aligning with AMX0035’s dual action targeting protein misfolding and oxidative stress.

3. 💊 Current Management Approaches and Unmet Needs

Treatment is supportive and symptom-specific, involving insulin therapy, hearing aids, visual supports, and hydration strategies. No approved therapies halt disease progression, making disease-modifying approaches like AMX0035 a potential breakthrough in altering the natural course.

4. 🧪 AMX0035 Mechanism of Action in Neurodegeneration

AMX0035 combines sodium phenylbutyrate (a chemical chaperone) and taurursodiol (a bile acid), aiming to reduce ER stress and mitochondrial dysfunction. Originally studied in ALS, its mode of action fits the cellular pathology of Wolfram syndrome, suggesting broader applicability in rare neurodegenerative conditions.

5. 🧩 Challenges in Rare Disease Trials and Regulatory Pathways

Neurologists should be aware of the complexity of designing trials for ultra-rare disorders, including endpoints, recruitment, and regulatory incentives. The HELIOS trial highlights how patient-reported outcomes and metabolic biomarkers can serve as meaningful indicators in early-phase research.

📚 References

1. Urano, F. (2021). Wolfram syndrome: Diagnosis, management, and emerging treatments.Current Opinion in Pediatrics, 33(6), 642–649.
2. Barrett, T. G., et al. (1995). Wolfram (DIDMOAD) syndrome.Practical Diabetes International, 12(3), 102–104.
3. Lu, Y., et al. (2014). Endoplasmic reticulum stress and its role in neurodegenerative diseases.Molecular Neurobiology, 49(1), 232–242.
4. La Morgia, C., et al. (2020). Mitochondrial dysfunction and neurodegeneration in Wolfram syndrome.Neurobiology of Disease, 143, 105014.
5. Paganoni, S., et al. (2020). Trial of AMX0035 for ALS.New England Journal of Medicine, 383, 919–930.
   – Original study demonstrating AMX0035’s therapeutic impact in ALS.
6. Hershey, T., et al. (2012). Wolfram syndrome: Structural brain abnormalities linked to cognitive deficits.Neurology, 79(6), 616–624.
7. Abreu, D., et al. (2021). Targeting ER stress and mitochondrial dysfunction in Wolfram syndrome with AMX0035.Orphanet Journal of Rare Diseases, 16, 97.
8. European Medicines Agency. (2023). Orphan designation for AMX0035 in Wolfram syndrome. Regulatory documentation.
9. Strom, T. M., et al. (1998). Mutations in WFS1 cause Wolfram syndrome.Nature Genetics, 20(4), 291–293.
10. Inoue, H., et al. (2020). Therapeutic approaches for Wolfram syndrome: Drug repurposing and disease-modifying strategies.Frontiers in Endocrinology, 11, 572305.